Abstract Number: 2696 • 2019 ACR/ARP Annual Meeting
Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Canakinumab (CAN) is an efficacious option for treatment of systemic juvenile idiopathic arthritis (sJIA). However, it is still disputable whether long-term therapy is efficacious…Abstract Number: 804 • 2019 ACR/ARP Annual Meeting
STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis
Background/Purpose: Gain-of-function mutations in TMEM173 encoding STING (Stimulator of Interferon Genes) underlie a novel type I INF termed SAVI syndrome. It is characterized by a…Abstract Number: 2699 • 2019 ACR/ARP Annual Meeting
Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, leading to ocular complications and blindness when not adequately treated. First…Abstract Number: 915 • 2019 ACR/ARP Annual Meeting
Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis
Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) has gained increasing popularity for the measurement of the level of disease activity in patients with juvenile…Abstract Number: 2701 • 2019 ACR/ARP Annual Meeting
Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In TurkEy: A Retrospective Study, JUPITER
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a chronic childhood arthritis with onset before age of 16 and has a significant degree of morbidity that negatively…Abstract Number: 916 • 2019 ACR/ARP Annual Meeting
Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Macrophage activation syndrome (MAS) is the most severe complication of systemic juvenile idiopathic arthritis (sJIA) and its adult equivalent, adult-onset Still’s disease (AOSD). Because…Abstract Number: 2702 • 2019 ACR/ARP Annual Meeting
Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group
Background/Purpose: The OMERACT Juvenile Idiopathic Arthritis Core Set Working Group formed in 2015 as an international initiative to revise the existing Core Set with relevant…Abstract Number: 1125 • 2019 ACR/ARP Annual Meeting
Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a common, chronic rheumatic disease of childhood that carries substantial economic impact on patients (pts) and families1. The objective…Abstract Number: 2704 • 2019 ACR/ARP Annual Meeting
Injection Fear in Juvenile Idiopathic Arthritis Patients Using Injectable Medications
Background/Purpose: Injectable medications are frequently used to treat Juvenile Idiopathic Arthritis (JIA). Fear of pain and needle fear have been identified as barriers to injectable…Abstract Number: 170 • 2019 ACR/ARP Annual Meeting
Evaluating an Illustrated Storybook for Children with Juvenile Idiopathic Arthritis
Background/Purpose: While juvenile idiopathic arthritis (JIA) is a common pediatric rheumatic disease, there is a lack of available child-friendly patient education materials. An illustrated storybook…Abstract Number: 1174 • 2019 ACR/ARP Annual Meeting
Prevalence of Subclinical Sacroiliitis in Young Patients with Inflammatory Bowel Disease Revealed by Entero-MRI
Background/Purpose: Sacroiliitis is one of the extraintestinal manifestations associated with inflammatory bowel disease (IBD), and may be underdiagnosed especially in the pediatric age. MR-enterography (Entero-MRI)…Abstract Number: 2705 • 2019 ACR/ARP Annual Meeting
Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis
Background/Purpose: Mental health disorders are thought to be common in patients with rheumatic disease, but studies examining behavioral issues in patients with juvenile idiopathic arthritis…Abstract Number: 2378 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…Abstract Number: 2389 • 2018 ACR/ARHP Annual Meeting
Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)
Background/Purpose: It is widely accepted that the treatment goal for juvenile idiopathic arthritis (JIA) is remission. PR-COIN, a quality improvement collaborative comprised of pediatric rheumatology…Abstract Number: 2391 • 2018 ACR/ARHP Annual Meeting
Methotrexate Polyglutamates As an Evaluation Tool for Appropriate Dosage of Oral Methotrexate Administration in Pediatric Patients
Background/Purpose: Since MTX metabolism varies depending on age and dosage, we need to know optimal MTX administration method in children. We performed multi-center prospective study…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 19
- Next Page »